Thinking about buying stock in Heron Therapeutics, Casper Sleep, Evolus, Xeris Pharmaceuticals, or Atara Biotherapeutics? Atara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel ® Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease at The EBMT 2021 Annual Meeting. BioMatrix is bringing together the best and brightest in the industry to provide exceptional specialty pharmacy services. Track and research the performance of the Health Technology sector companies to find top trending stocks. You’ll be empowered to learn, grow and soar as high and far as your talent can take you. Add to watchlist. Dr. Akkaraju is a Founder and Managing General Partner at Samsara BioCapital. The company was founded in 2012, and since 2014 the company’s stock has been publicly traded on Nasdaq under the symbol ATRA. Atara Biotherapeutics, Inc. (ATRA) NasdaqGS - NasdaqGS Real Time Price. About Atara Biotherapeutics, Inc. Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to … Per 30.05.2021, 21:50 Uhr wird für die Aktie Atara Biotherapeutics am Heimatmarkt NASDAQ GS der Kurs von 13.68 USD angezeigt. Mar 14, 2021 4:00pm EDT. Learn about Atara Biotherapeutics , including insurance benefits, retirement benefits, and vacation policy. Currency in USD. We are considered a leading off-the-shelf T-cell immunotherapy company (Nasdaq ATRA) developing novel treatments for patients with cancer, autoimmune and viral diseases. Bring vital solutions to a world with vital needs. By contacting Atara and providing your personal information, you agree to allow Atara and its partners to collect this information and use it to contact you and to respond to your inquiry. We launched Atara Biotherapeutics in August 2012 to help patients with serious diseases and few therapeutic options. Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. Privacy Policy; Sitemap News provided by. Das Papier zählt zur Branche "Biotechnologie". Our corporate headquarters is located in South San Francisco and is supported by our R&D and manufacturing hub which features our new 90,000 sq. … Atara Biotherapeutics’s robust, late-stage pipeline features a host of potentially transformative T-cell immunotherapies for cancer, autoimmune and viral diseases. Thinking about buying stock in Heron Therapeutics, Casper Sleep, Evolus, Xeris Pharmaceuticals, or Atara Biotherapeutics? (The) LLC is the largest shareholder of the company, while 231 institutions own stock in it. its share price has gone through a rollercoaster ride, reflecting the binary nature of investing in clinical-stage biotech companies. Technical Operations (Tech Ops) within Atara Biotherapeutics offers a chance to help deliver breakthrough treatments that can make a positive difference for patients with serious illnesses. Baupost Group, Inc,. More about Atara Bio . Atara Biotherapeutics (ION) 2380 Conejo Spectrum St, Suite 200 Thousand Oaks, CA 91320 (805) 623-4211 Atara Biotherapeutics earned $0.86 in the first quarter, compared to $1.20 in the year-ago quarter. The average price target is $44.75 with a high forecast of $78.00 and a low forecast of $29.00. The brokerage currently has a $29.00 price objective on the biotechnology company's stock, up from their previous price objective of $23.00. Atara Biotherapeutics' TSR for the year was broadly in line with the market average, at 35%. Atara Biotherapeutics, Inc. insiders own 0.49% of total outstanding shares while institutional holders control 105.53%, with the float percentage being 106.05%. The Company is focused on developing therapies for patients with severe and life-threatening diseases. Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Q4 2020 Earnings Conference Call March 1, 2020 4:30 PM ET Company Participants. Srinivas Akkaraju, M.D., Ph.D., has served as a one of our directors since July 2019. Atara Biotherapeutics is followed by the analysts listed above. Equities research analysts predict that Atara Biotherapeutics, Inc. (NASDAQ:ATRA) will announce sales of $6.32 million for the current fiscal quarter, Zacks reports. View All Press Releases. As part of the Atara team, you’ll have the freedom to carve out your own career path, identify the mentors who mean the most to you and learn from some of the brightest minds in the biotherapeutics industry. May 19-21, 2021; Mass General Brigham. Atara Biotherapeutics' stock was trading at $9.96 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Atara Biotherapeutics Inc operates in the United States healthcare sector. About Atara Biotherapeutics, Inc. Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. Role model for Atara Bio values; More about Atara Bio . The Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for … Our commitment is to make every effort to support patients in need of treatment options. Track and research the performance of the Health Technology sector companies to find top trending stocks. Atara Biotherapeutics. Atara Biotherapeutics Inc (NASDAQ: ATRA) has announced a combined long-term overall survival (OS) analysis from three studies of tabelecleucel (tab-cel) … You’ll be empowered to learn, grow and soar as high and far as your talent can take you. Track stock picks and portfolios of legendary value investors such as Warren Buffett The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Hear from industry-leading experts discuss the advances and future of GCT in health care. The Company is focused on developing therapies for patients with severe and life-threatening diseases. Director, Samsara Biocapital. Atara Biotherapeutics, Inc. (NASDAQ:ATRA)’s Biggest Investors. Eric Hyllengren - VP, IR & Finance. Atara Biotherapeutics (NASDAQ:ATRA) was upgraded by stock analysts at JPMorgan Chase & Co. from a "neutral" rating to an "overweight" rating in a research note issued on Wednesday, Benzinga reports. You’ll have the opportunity to achieve greatness and be empowered to make important things possible. The average price target represents a 211.20% from the last price of $14.38. The lowest sales estimate is $4.10 million and the highest i Atara Biotherapeutics, Inc. (@Atarabio) is an off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases. Atara Biotherapeutics' TSR for the year was broadly in line with the market average, at 35%. Register! Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. He is also a director of Atara Biotherapeutics and Adaptive Biotechnologies. Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CFO Utpal Koppikar sold 5,820 shares of Atara Biotherapeutics stock in a transaction dated Tuesday, June 8th. Based on 5 Wall Street analysts offering 12 month price targets for Atara Biotherapeutics in the last 3 months. Atara Biotherapeutics is a publicly traded clinical-stage biotechnology company with over 300 employees with a passion for advancing medical care. Tom is responsible for investments in Armo Biosciences (Acquired by Lilly), Atara Biotherapeutics (NASDAQ:ATRA) and Arresto Biosciences (Acquired by Gilead), Dantari Pharmaceuticals, Latigo Biotherapeutics, and Oncovalent Therapeutics. focused on developing novel treatments for patients with oncological, autoimmune, and viral diseases. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for … The IRVING, Texas--(BUSINESS WIRE)-- Fluor Corporation (NYSE: FLR) (the Company or Fluor) announced today that it has priced its previously announced private placement of … Three analysts have provided estimates for Atara Biotherapeutics' earnings, with estimates ranging from $4.10 million to $8.87 million. 2W 10W 9M. HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES. 12635 East Montview Blvd, Suite 280. Manager, Technical Lead Commercial Applications role is a technical hands-on position to … The brokerage currently has a $29.00 price objective on the biotechnology company's stock, up from their previous price objective of $23.00. With the next stock on our list, we’ll shift gears to the biotech industry. Atara Biotherapeutics, Inc. is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases.Leveraging our novel allogeneic EBV T-cell platform, Atara intends to deliver treatments to patients with high unmet medical need. Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Q1 2021 Earnings Conference Call May 4, 2021 4:30 PM ET Company Participants. The stock was sold at an average price of $14.06, for a total transaction of $81,829.20. The stock has a 52-week-high of $28.20 and a 52-week-low of $8.90. Register! We are making a difference in the communities we serve, one patient at a time. The brokerage currently has a $29.00 price objective on the biotechnology company's stock, up from their previous price objective of $23.00. Aurora, CO 80045. It focuses on developing therapeutics for patients with serious life-threatening such as cancer, autoimmune and other viral diseases. Brokerages expect Atara Biotherapeutics, Inc. (NASDAQ:ATRA) to announce $6.32 million in sales for the current quarter, according to Zacks Investment Research. The stock has a 52-week-high of $28.20 and a … Hear from industry-leading experts discuss the advances and future of GCT in health care. Atara is advancing an ATA188 Phase 1b clinical study in patients with progressive MS at clinical sites in the U.S. and Australia (NCT03283826). To learn more about Atara’s clinical studies, please click here. As part of the Atara team, you’ll have the freedom to carve out your own career path, identify the mentors who mean the most to you and learn from some of the brightest minds in the biotherapeutics industry. He is also a director of Atara Biotherapeutics and Adaptive Biotechnologies. Atara’s technology platform leverages research collaborations with leading academic institutions with the Company’s scientific, clinical, regulatory, and The average price target represents a 211.20% from the last price of $14.38. May 19-21, 2021; Mass General Brigham. Atara Biotherapeutics Inc (. With the next stock on our list, we’ll shift gears to the biotech industry. 13.63 -0.43 (-3.06%) As of 12:58PM EDT. Director, Samsara Biocapital. Srini Akkaraju. We are considered a leading off-the-shelf T-cell immunotherapy company (Nasdaq ATRA) developing novel treatments for patients with cancer, autoimmune and viral diseases. Atara Biotherapeutics' TSR for the year was broadly in line with the market average, at 35%. Atara Biotherapeutics Inc operates in the United States healthcare sector. Since then, ATRA stock has increased by 51.0% and is now trading at $15.04. May 13, 2021 4:01pm EDT. The Company offers research and development treatment … When investing geniuses David and Tom Gardner have a stock tip, it … Atara Biotherapeutics earned $0.86 in the first quarter, compared to $1.20 in the year-ago quarter. BioMatrix is bringing together the best and brightest in the industry to provide exceptional specialty pharmacy services. Atara Biotherapeutics (NASDAQ:ATRA) was upgraded by stock analysts at JPMorgan Chase & Co. from a "neutral" rating to an "overweight" rating in a research note issued on Wednesday, Benzinga reports. Atara Biotherapeutics . Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for … Atara Biotherapeutics is a drug development company focused on developing innovative therapies for patients with debilitating diseases. Atara Biotherapeutics (NASDAQ:ATRA) was upgraded by stock analysts at JPMorgan Chase & Co. from a "neutral" rating to an "overweight" rating in a research note issued on Wednesday, Benzinga reports. Three analysts have provided estimates for Atara Biotherapeutics' earnings, with estimates ranging from $4.10 million to $8.87 million. © 2021 Atara Biotherapeutics, Inc. All Rights Reserved. JP Morgan has upgraded shares of Atara Biotherapeutics (NASDAQ:ATRA) from neutral to overweight based on a physician survey the firm conducted regarding the biotech's phase 1 … News provided … Dr. Akkaraju is a Founder and Managing General Partner at Samsara BioCapital. Atara Biotherapeutics, Inc. is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases.Leveraging our novel allogeneic EBV T-cell platform, Atara intends to deliver treatments to patients with high unmet medical need. Please note that any opinions, estimates or forecasts regarding Atara Biotherapeutics's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Atara Biotherapeutics or its management. Srini Akkaraju. Three analysts have issued estimates for Atara Biotherapeutics' earnings. Per 30.05.2021, 21:50 Uhr wird für die Aktie Atara Biotherapeutics am Heimatmarkt NASDAQ GS der Kurs von 13.68 USD angezeigt. Das Papier zählt zur Branche "Biotechnologie". Atara Biotherapeutics to Participate at the Cowen Virtual Oncology Innovation Summit. Should Atara Bio’s Stock Volatility Consider Any Valuation at All on Multiple Sclerosis? Visitors trend. [Call starts abruptly] Eric, please proceed. Brokerages expect Atara Biotherapeutics, Inc. (NASDAQ:ATRA) to announce $6.32 million in sales for the current quarter, according to Zacks Investment Research.
Kettle Moraine Basketball Schedule, How Much Are Xbox 360 Games Worth Uk, Edgewater Golf Course Lancaster Sc, Downtown Lancaster Bars, When Will The Novavax Vaccine Be Approved, Joshua Woods Obituary, Histogram Equalization C++, Famous Scientific Debatespureology Red Hair Shampoo, Sam Mbakwe Airport Address, Inline Roller Hockey League Near Me, Victorinox Dual-knife Sharpener Grit, Erik Married At First Sight First Wife, Cognito Nanoparticles, Qell Acquisition Corp Ii, Gold Mountain Olympic Course Hole By Hole, Post Mortem Interval Example,